Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Contract/Agreement, Product/Service

Prestige BioPharma and Dr. Reddy's announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia


Prestige BioPharma Ltd. (KRX: 950210) and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as "Dr. Reddy's") today announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of Prestige BioPharma's proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia.

Prestige BioPharma's trastuzumab (HD201) is a proposed biosimilar to Roche's Herceptin® and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer. Trastuzumab targets human epidermal growth factor 2 (HER2). In some types of cancer cells, HER2 is overexpressed and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells.

The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia. Under this partnership, Prestige BioPharma will be responsible for sustainable commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr. Reddy's will be responsible for local registrations, marketing and sales in the licensed territories.

Lisa S. Park, CEO of Prestige BioPharma, commented: "We are delighted to establish a partnership with Dr. Reddy's for key Latin American and Southeast Asian markets. Dr. Reddy's is the ideal partner to commercialize our lead biosimilar in these territories. With this collaboration, we look forward to further strengthening the value of our biosimilar programs in global markets."

M.V. Ramana, CEO ? Branded Markets (India & Emerging Markets), Dr. Reddy's, said: "In keeping with our purpose of accelerating access to affordable and innovative medicines, we are happy to bring this life-saving drug to patients in need. Our partnership with Prestige BioPharma will help us combine their established expertise in the area of biosimilars with our commercial strengths and growth ambition in these markets. This is in line with our stated intention to create a portfolio of oncology products and expand our biosimilar offerings in Emerging Markets."

About Prestige BioPharma Limited:
PRESTIGE BIOPHARMA LTD (PBP) is a Singapore-based biopharmaceutical company with operations in USA and Korea, specialising in the discovery and development of biosimilars, novel antibodies and vaccines. PBP strives to become a global innovator through the development of first-in-class mAbs including PBP1510 anti-PAUF mAb for pancreatic cancer that recently obtained orphan designation from FDA, EMA and MFDS. PBP's rich portfolio of biosimilars in various stages including HD204 bevacizumab in global Phase 3, PBP1502 adalimumab in Phase 1 and others, is aimed to provide affordable quality medicines to those who need. PBP's business also includes alliance vaccine development and production, starting with the partnered commercial production of COVID-19 vaccines. For more information, please visit www.prestigebiopharma.com.

About Dr. Reddy's:
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its businesses, Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include ? USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.


These press releases may also interest you

at 01:35
Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today...

at 01:29
On January 13, 2022, Green Valley (Shanghai) Pharmaceuticals Co., Ltd. received the letter from the US Food and Drug Administration (FDA) on the Investigational New Drug (IND) application for the global multi-center phase-II clinical trial of...

at 01:00
42% of the market's growth will originate from North America for the small molecule API Market The US is a key market for small molecule API in the region. However, the market growth rate in this region will be slower than the growth of the market in...

16 jan 2022
MicroPort CRM, a pioneering company in the field of Cardiac Rhythm Management, headquartered in France, recently received PMDA Japanese regulation agency approval for its latest range of implantable pacemakers, Alizea. The devices are equipped with...

16 jan 2022
Models of BGI Genomics' Huo-Yan Air Laboratory, a star nucleic acid-testing mobile lab product of the Chinese giant, were displayed at the China Pavilion of Expo 2020 Dubai during January 11-13. Compared with regular COVID-testing labs, Huo-Yan Air...

16 jan 2022
Jacobio's self-developed global first-in-class drug Aurora A inhibitor  JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US. Jacobio plans to initiate a Phase I/IIa clinical trial in patients with...



News published on 9 december 2021 at 00:55 and distributed by: